Clinical trials: Cardiac Events
Coronary Artery Disease
Heparin Dose and Post Operative Bleeding in Cardiopulmonary Bypass Patients
Blood is anticoagulated using a drug named heparin during open-heart surgery to allow it to safely pass through the heart-lung machine which pumps the blood throughout the body during the surgery.
- Trial name
- NCT01574105
- Where
- 2 sites in Canada
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- University of Saskatchewan
Arrhythmia, Palpitations, Lightheadedness
Validation of an iPhone-based Event Recorder for Arrhythmia Detection
In this study, we will evaluate the diagnostic yield of the new AliveCor device versus a 14 day event monitor with the use of both devices simultaneously.
- Trial name
- NCT02005172
- Testing
- Alivecor monitor and 14 day event monitor
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University at Buffalo
Coronary Artery Disease, Angina Pectoris
Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)
This study will evaluate the efficacy of ranolazine as compared with placebo when used as part of standard medical therapy in chronic angina subjects with incomplete revascularization post-percutaneous coronary intervention (PCI…
- Trial name
- RIVER-PCI (NCT01442038)
- Testing
- Ranolazine
- Where
- 218 sites in United States, Austria and 13 more
- Volunteers
- 2,651 people
- Sponsor
- Gilead Sciences
Acute Coronary Syndrome
The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial
This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or urgent coronary revascularization (e.g.
- Trial name
- SOLID-TIMI 52 (NCT01000727)
- Testing
- Darapladib 160 mg, Standard Therapy
- Where
- 914 sites in United States, Argentina and 34 more
- Volunteers
- 13,026 people
- Sponsor
- GlaxoSmithKline
Heart Failure, Type 2 Diabetes Mellitus
Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
The primary objective of the study was to compare the effect of sotagliflozin to placebo on total occurrences of cardiovascular (CV) death, hospitalization for heart failure [HHF], and urgent visit for heart failure [HF] in…
- Conditions
- Heart Failure, Type 2 Diabetes Mellitus, Chronic Kidney Diseases
- Trial name
- SCORED (NCT03315143)
- Testing
- Sotagliflozin
- Where
- 754 sites in United States, Argentina and 43 more
- Volunteers
- 10,584 people
- Sponsor
- Lexicon Pharmaceuticals
Atherosclerotic Cardiovascular Disease
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
Primary Objective: To compare the effect of alirocumab with placebo on the occurrence of cardiovascular (CV) events (composite endpoint of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), fatal and…
- Trial name
- NCT01663402
- Testing
- Alirocumab, LMT
- Where
- 1,388 sites in United States, Argentina and 55 more
- Volunteers
- 18,924 people
- Sponsor
- Sanofi
Acute ST Elevation Myocardial Infarction
How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention
The purpose of this study is to compare unfractionated heparin (UFH) and bivalirudin in the performance and subsequent outcomes of Primary percutaneous coronary intervention. This will be a pragmatic trial.
- Trial name
- HEAT-PPCI (NCT01519518)
- Testing
- unfractionated heparin, Bivalirudin
- Where
- United Kingdom
- Volunteers
- 1,829 people
- Sponsor
- Liverpool Heart and Chest Hospital NHS Foundation Trust
Ventricular Tachycardia, Ventricular Fibrillation
DATAS: The Dual Chamber & Atrial Tachyarrhythmias Adverse Events Study
The Dual Chamber \& Atrial Tachyarrhythmias Adverse Events Study (DATAS) was designed to analyze the ability of dual chamber ICDs, to reduce clinically significant adverse events as compared to single chamber ICD in a non…
- Conditions
- Ventricular Tachycardia, Ventricular Fibrillation, Defibrillators, Implantable
- Trial name
- DATAS (NCT00157820)
- Testing
- Single Chamber Implantable Cardioverter Defibrillator, Dual Chamber implantable cardioverter defibrilator
- Volunteers
- 354 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Coronary Artery Disease
The Dual Antiplatelet Therapy Study (DAPT Study)
The DAPT Study is a double blind randomized controlled trial intended to determine the appropriate duration for dual antiplatelet therapy (the combination of aspirin and a second anti-clotting medication) as well as the safety…
- Trial name
- NCT00977938
- Testing
- Clopidogrel & Aspirin, Prasugrel & Aspirin
- Where
- 256 sites in United States, Australia and 8 more
- Volunteers
- 25,682 people
- Sponsor
- Baim Institute for Clinical Research
Myocardial Ischemia, Acute Coronary Syndrome
Cardiac Rehabilitation for Heart Event Recovery (HER)
The purpose of this study is to compare women's cardiac rehabilitation program adherence across three program models.
- Conditions
- Myocardial Ischemia, Acute Coronary Syndrome, Heart Disease, Coronary Artery Disease
- Trial name
- CR4HER (NCT01019135)
- Testing
- Cardiac Rehabilitation
- Where
- 5 sites in Canada
- Volunteers
- 169 people
- Sponsor
- University Health Network, Toronto
Saphenous Vein Graft Disease
Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial)
During coronary artery bypass graft surgery (CABG), saphenous vein from the leg is used to bypass the atherosclerotic blockages in the arteries of the heart.
- Trial name
- ACTIVE (NCT01528709)
- Testing
- Atorvastatin 80 mg daily, Atorvastatin 10 mg daily
- Where
- 2 sites in United States, Canada
- Volunteers
- 173 people
- Sponsor
- Boca Raton Regional Hospital
Acute Coronary Syndrome, TIA
Early Psychological Intervention to Prevent Cardiovascular Event-Induced PTSD (REACH Sub-study)
The overall purpose of this project is to determine the feasibility of conducting a randomized clinical trial that compares written exposure therapy with usual care among patients at risk for cardiovascular event-induced PTSD.
- Conditions
- Acute Coronary Syndrome, TIA, Stroke, Cardiac Arrest
- Trial name
- NCT03605693
- Testing
- Written Exposure Therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Columbia University
Atrial Fibrillation
Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa
This study is being conducted to collect data on the management of gastrointestinal and urogenital bleeding events occurring in patients with atrial fibrillation taking dabigatran etexilate.
- Trial name
- NCT02022020
- Where
- 22 sites in United States, Canada
- Volunteers
- 220 people
- Sponsor
- Boehringer Ingelheim
STEMI, NSTEMI
Assessment of Individual Risk of Cardiovascular Events by Platelet FcGammaRIIa
This is a Prospective, Observational Multicenter Non-Interventional Cohort Study. The primary objective is to determine whether platelet expression of FcγRIIa is associated with risk of myocardial infarction (MI), stroke and…
- Trial name
- NCT05175261
- Testing
- Prolocor pFCG test
- Where
- United States
- Volunteers
- 764 people
- Sponsor
- Prolocor, Inc
Acute Coronary Syndrome
Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event
The purpose of this study is to determine the effect of VIA-2291 as compared to placebo on vascular inflammation following 24 weeks of dosing.
- Trial name
- NCT00552188
- Testing
- VIA-2291
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- Tallikut Pharmaceuticals, Inc.
Stable Angina
Aspirin Resistance and Percutaneous Coronary Intervention (PCI)
The objective of this study is to evaluate if aggressive antiplatelet therapy would reduce ischemic events in aspirin (ASA) resistant patients after percutaneous coronary intervention (PCI).
- Trial name
- RESIST (NCT01103440)
- Testing
- Intravenous Glycoprotein inhibitor + ASA, Clopidogrel, Antiplatelet Therapy (ASA, Clopidogrel)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Non ST Segment Elevation Acute Coronary Syndrome
Different LD of Ticagrelor for Antiplatelet Effect in Patients With Non-ST-segment Elevation ACS Undergoing PCI
It is designed to test the hypothesis that high loading dose(360mg) ticagrelor versus conventional loading dose(180mg) will result in a higher inhibition of platelet aggregation(IPA) without increasing the bleeding events.
- Trial name
- NCT01962428
- Testing
- ticagrelor
- Where
- 2 sites in China
- Volunteers
- 250 people
- Sponsor
- General Hospital of Chinese Armed Police Forces
Paroxysmal Atrial Fibrillation
Oral Anticoagulation Therapy Pilot Study
The objective of this study is to determine the safety of discontinuing oral anticoagulation therapy in high risk patients who have had a successful cardiac ablation and remain AF recurrence free for 3 months post ablation.
- Trial name
- OAT (NCT01959425)
- Testing
- Off OAT Group (Test), On OAT Group (Control)
- Volunteers
- 80 people
- Sponsor
- Biosense Webster, Inc.
Myocardial Infarction, Stroke
Women's Health Initiative Strong and Healthy Study
The WHISH trial applies state-of-the science behavioral principles and currently available technologies to deliver a physical activity intervention without face-to-face contact to ~25,000 older U.S. women expected to consent.
- Conditions
- Myocardial Infarction, Stroke, Cardiovascular Mortality, Hip Fractures
- Trial name
- WHISH (NCT02425345)
- Testing
- Physical Activity
- Volunteers
- 49,331 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Atrial Fibrillation, Hemorrhage
Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa
This study is being conducted to collect data on the management of major bleeding events occurring in patients with atrial fibrillation taking dabigatran etexilate.
- Trial name
- NCT02149303
- Testing
- Dabigatran 75 mg, Dabigatran 150 mg
- Where
- 5 sites in United States
- Volunteers
- 191 people
- Sponsor
- Boehringer Ingelheim